What does this research mean for the field?

Tislelizumab, whether used alone or in combination with chemotherapy, is a safe and effective treatment for non-small cell lung cancer that improves progression-free survival and objective response rates. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to assess the safety and efficacy of tislelizumab for treating non-small cell lung cancer (NSCLC).

December 8, 2023BMC Pulmonary MedicineOpen Access

The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials

View Full Paper

Ask AI

Bookmark

The aim is to assess the safety and efficacy of tislelizumab for treating non-small cell lung cancer (NSCLC).
Conducted a systematic review of randomized controlled trials (RCTs) until December 20, 2022.
Evaluated study quality using the revised Cochrane risk-of-bias tool (RoB2).
Included trials that focused on tislelizumab's effects in patients with locally advanced or metastatic NSCLC.
Four RCTs included with 1565 patients showed better progression-free survival (PFS) and objective response rate (ORR) for tislelizumab combined with chemotherapy.
Over 20% of grade ≥ 3 treatment-emergent adverse events (TEAEs) were due to decreased hematologic indexes in combination therapy.
The death rate from TEAEs in the tislelizumab plus chemotherapy arms ranged from 3.2% to 4.2%.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Systematic review evaluates tislelizumab alone or with chemotherapy for NSCLC, suggesting effective treatment options.

Cite This Study

Sorkhabi et al. (2023) studied this question.

synapsesocial.com/papers/6a337e48a24a506fc919a144 https://doi.org/10.1186/s12890-023-02755-3

View Full Paper

Ask AI

Bookmark

The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials

Key Points

Discussion

Implication

Cite This Study

The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider